Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRA-PCI study of SCH 530348 in non-emergent percutaneous coronary intervention
2005-001890-83Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing SCH 530348 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Incidence of TIMI major plus minor bleeding through end of treatment in the primary evaluable cohort. Started Jan 2006; status: terminated.
02
Drugs
vorapaxar
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-001890-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001890-83.